Fig. 7

Concomitant blockade of WNT and MAPK signalling restricts the emergence of drug resistance. a APC-mutated CRC cells and their MAPK-resistant derivatives were transfected with plasmid expressing intact WT APC or control electroporation buffer (mock). After transfection, the cells were seeded in 48-wells plates with or without cetuximab (DIFI cells), dabrafenib + cetuximab (WIDR cells). After 48 h, cell viability was assayed by ATP assay. Representative graphs of two independent experiments for each cell line are reported. Results represent means ± SD of three independent wells. Single points indicate results of single experiments. b BRAF-mutated CRC cells were treated with dabrafenib (BRAFinhib.), dabrafenib + cetuximab (EGFRinhib.), LGK974 (WNTinhib.), or dabrafenib + LGK974, until secondary resistance emerged